Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash from Operations: 2020-2025

Historic Cash from Operations for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to -$25.2 million.

  • Caribou Biosciences' Cash from Operations rose 22.84% to -$25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.7 million, marking a year-over-year decrease of 1.26%. This contributed to the annual value of -$138.2 million for FY2024, which is 48.14% down from last year.
  • Caribou Biosciences' Cash from Operations amounted to -$25.2 million in Q3 2025, which was up 10.88% from -$28.3 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Cash from Operations high stood at $20.3 million for Q1 2021, and its period low was -$37.2 million during Q1 2024.
  • Moreover, its 3-year median value for Cash from Operations was -$28.8 million (2023), whereas its average is -$29.2 million.
  • In the last 5 years, Caribou Biosciences' Cash from Operations slumped by 206.70% in 2022 and then surged by 30.58% in 2023.
  • Quarterly analysis of 5 years shows Caribou Biosciences' Cash from Operations stood at -$21.4 million in 2021, then decreased by 17.09% to -$25.0 million in 2022, then climbed by 14.63% to -$21.4 million in 2023, then slumped by 65.91% to -$35.5 million in 2024, then increased by 22.84% to -$25.2 million in 2025.
  • Its Cash from Operations was -$25.2 million in Q3 2025, compared to -$28.3 million in Q2 2025 and -$36.7 million in Q1 2025.